Article Sidebar

PDF
Date Published: 05/01/2022
Abstract Views: 293
Views PDF: 181
DOI: https://doi.org/10.51298/vmj.v508i1.1532
Issue
Vol. 508 No. 1 (2021)
Section
Các bài báo
How to Cite
Đình Quang, T. ., & Thị Thái Hòa, N. . (2022). SIDE-EFFECTS OF FIRST LINE PACLITAXEL – CARBOPLATIN REGIMEN FOR STAGE IV NON-SMALL CELL LUNG CANCER IN OLDER ADULTS. Vietnam Medical Journal, 508(1). https://doi.org/10.51298/vmj.v508i1.1532

SIDE-EFFECTS OF FIRST LINE PACLITAXEL – CARBOPLATIN REGIMEN FOR STAGE IV NON-SMALL CELL LUNG CANCER IN OLDER ADULTS

Trần Đình Quang1,, Nguyễn Thị Thái Hòa2
1 Friendship Hospital
2 K Hospital

Main Article Content

Abstract

Objective: EstimateSide-effects of first line Paclitaxel – Carboplatin regimen for stage IV non-small cell lung cancer in elderly patientsat Huu Nghi Hospital. Patients and Methods: Retrospective and prospective estimated side effects of 51 patients older than 60 years with stage IV non-small cell lung cancer receiving Paclitaxel-Carboplatin asfirst line chemotherapyat Huu Nghi Hospital from January 2016 to December 2021. Results: Of our 51 patients, the rate of leukopenia,neutropeniawere 25,5% and 37,3% respectively. Leukopenia andneutropenia grade 1/2  occurred  in 19,6% and 27,4%. Anaemia and thrombopenia were 29,4% and 13,7%. The rate of vomitingand nausea were 19,6% and 9,8%.Diarrhea occurred in 11,8%. The rate of peripheralneuropathy and osteoarthritis were 17,6% and 21,6%. Conclusions: Side-effects of  the regimen mostly at grade 1 or 2, safely to apply on older adults.

Article Details

Keywords

Paclitaxel-Carboplatin, Non-small cell lung cancer, Older adults

References

1. Lê Tuấn Anh, Nguyễn Ngọc Bảo Hoàng (2013). Đặc điểm lâm sàng và điều trị của 1158 bệnh nhân ung thư phổi tại Trung tâm Ung bướu Chợ Rẫy. Y học thực hành, 8(8), 7869.
2. Nguyễn Trọng Hiếu (2012), Đánh giá hiệu quả và độc tính phác đồ Paclitaxelnano/Carboplatin trong ung thư phổi không tế bào nhỏ giai đoạn IIB-IV, Luận văn thạc sỹ y học, Đại học Y Hà Nội.
3. Trương Thị Kiều Oanh (2017), Đánh giá đáp ứng hóa chất phác đồ Paclitaxel-Carboplatin bước 1 ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn IIIB-IV trên 60 tuổi, Luận án thạc sỹ y học, Đại học Y Hà Nội.
4. Bray F, Ferlay J et al (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2018 Nov, 68(6), 394-424.
5. B. Biesma, A. N. M. Wymenga, A. Vincent et al (2011). Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin–gemcitabine or carboplatin–paclitaxel: NVALT-3 a phase III study. Annals of Oncology, 22, 1520–1527.
6. Hala Mohamed El-Shenshawy, Saleh Taema, Eman El-Zahaf et al (2012). Advanced non-small cell lung cancer in elderly patients : The standard every 3-weeks versus weekly paclitaxel with carboplatin. Egyptian Journal of Chest Diseases and Tuberculosis, 61, 485 –493.
7. Junya Zhu, Dhruv B. Sharma, Aileen B. Chen, et al(2013). Comparative Effectiveness of Three Platinum – Doublet Chemotherapy Regimens in Elderly Patients With Advanced Non–Small Cell Lung Cancer. Cancer, 119, 2048-2060.